Background

The Challenge of Treating Leukemia with Numerous Mutation Variables

Acute Myeloid Leukemia (AML) is a highly aggressive and difficult-to-treat blood cancer with a poor prognosis. Conventional medical practice has primarily focused on deciphering the DNA sequence mutations of cancer cells to categorize patients and prescribe drugs. However, even among patients with the same mutations, significant variations in treatment response and the likelihood of relapse have been consistently observed. This has led to the growing recognition that epigenetic alterations, which regulate traits through biochemical changes within the body without altering the gene sequence, play a crucial role in promoting the malignant transformation of leukemia.

Chromatin Openness, a Key to Gene Function

Chromatin, which contains the cell's genetic information, exists in different states of openness. Chromatin openness, which directly determines gene expression, is a measure of how accessible the chromatin is. The more open a region of chromatin, the easier it is for transcription factors to bind and activate specific genes. Research that systematically maps the chromatin openness status, which varies among leukemia cells, in a large cohort of clinical patients has been technically challenging until now.

Key Findings

An Epigenetic Map Created by Deciphering the Genomes of 1,563 Patients

To overcome this limitation, an international research team established the eCHROMA cohort, consisting of samples from 1,563 AML patients. The researchers applied an Assay for Transposase-Accessible Chromatin sequencing (ATAC-seq) to analyze the epigenetic structure of each patient in a three-dimensional manner. The analysis resulted in the creation of a map that classifies patients into 16 distinct epigenomic subgroups.

The newly established classification system effectively addresses the limitations of existing gene mutation analysis methods. The 16 subgroups exhibit unique gene co-mutations, stages of cancer cell differentiation, levels of DNA methylation, and the distribution of active super-enhancers that regulate transcription. The researchers further conducted single-cell RNA sequencing (scRNA-seq) to confirm that the leukemia cells within patients maintain this epigenetic identity consistently.

A 30-Gene Signature to Aid in the Identification of High-Risk Groups

Furthermore, the study revealed that the response to specific therapies varies significantly depending on the subgroup. Patients who were previously considered unlikely to respond to treatment based on conventional genetic testing were found to exhibit excellent responses to drugs when analyzed using the epigenetic map. To enhance the practical applicability in clinical settings, the researchers developed a 30-gene expression signature to rapidly identify high-risk subgroups. This provides a means to significantly reduce the cost and time required for diagnosis.

Significance and Prospects

Expanding the Scope of Genomic Precision Medicine

This research clearly demonstrates that in the development of leukemia, mechanisms other than sequence mutations, namely epigenetic regulation, play a critical role in determining patient prognosis and drug response. It has been widely recognized that this study expands the scope of cancer research beyond the traditional focus on genetic mutations to include genomic structure and the activity of non-coding regions.

In clinical practice, this provides clues for designing personalized companion diagnostic models that link a patient's epigenetic status to appropriate treatments.

Future Challenges for Implementation in Clinical Practice

However, there are barriers to overcome before these findings can be fully implemented in clinical practice. Performing and interpreting complex genomic tests such as ATAC-seq in routine clinical settings poses challenges in terms of budget and specialized personnel. The 30-gene-based screening model developed by the research team must also be validated for reproducibility in independent cohorts of patients with different conditions before it can be adopted as a commercial test kit. Furthermore, follow-up studies are needed to accurately capture the dynamic changes in epigenetic status that occur during treatment.